Trials / Completed
CompletedNCT01423656
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects. The study is divided into one single dose part, one part to compare pharmacokinetics between gender and one multiple dose part.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 29102 | |
| DRUG | Placebo | Placebo Comparator: LEO 29102 vehicle |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2011-08-26
- Last updated
- 2025-02-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01423656. Inclusion in this directory is not an endorsement.